Jean-Frederic Viret - Dec 1, 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role
Chief Financial Officer
Signature
Valerie Pierce, Attorney-in-fact
Stock symbol
NGM
Transactions as of
Dec 1, 2023
Transactions value $
$0
Form type
4
Date filed
12/4/2023, 04:27 PM
Previous filing
Nov 8, 2023
Next filing
Apr 8, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +450K $0.00 450K Dec 1, 2023 Common Stock 450K $0.77 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest over a four-year period commencing November 3, 2023, with 1/4th of the shares vesting on November 3, 2024 and 1/48th of the shares vesting monthly thereafter.